Advances in cellular and humoral immunotherapy - implications for the treatment of poor risk childhood, adolescent, and young adult B-cell non-Hodgkin lymphoma

Br J Haematol. 2019 Jun;185(6):1055-1070. doi: 10.1111/bjh.15753. Epub 2019 Jan 6.

Abstract

Patients with relapsed, refractory or advanced stage B non-Hodgkin lymphoma (NHL) continue to have a dismal prognosis. This review summarises current and novel cellular and immunotherapy for these high-risk populations, including haematopoietic stem cell transplant, bispecific antibodies, viral-derived cytotoxic T cells, chimeric antigen receptor (CAR) T cells, and natural killer (NK) cell therapy, as discussed at the 6th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma on September 26th-29th 2018 in Rotterdam, the Netherlands, and explores the future of NK/CAR NK therapies.

Keywords: B-cell non-Hodgkin lymphoma; IL-15 superagonist; cellular immunotherapy; chimeric antigen receptor; stem cell transplantation.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Adolescent
  • Age Factors
  • Animals
  • Child
  • Child, Preschool
  • Combined Modality Therapy / adverse effects
  • Combined Modality Therapy / methods
  • Disease Management
  • Humans
  • Immunity, Cellular*
  • Immunity, Humoral*
  • Immunotherapy* / adverse effects
  • Immunotherapy* / methods
  • Lymphoma, B-Cell / immunology*
  • Lymphoma, B-Cell / metabolism
  • Lymphoma, B-Cell / therapy*
  • Lymphoma, Non-Hodgkin / immunology*
  • Lymphoma, Non-Hodgkin / metabolism
  • Lymphoma, Non-Hodgkin / therapy*
  • Young Adult